Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spanish charity aims to become key reference point for breast cancer info

This article was originally published in Clinica

Executive Summary

A leading Spanish breast cancer charity has revamped its internet presence, in a bid to become a "key reference point" for the 16,000 women who are diagnosed annually with breast cancer in the country. Ascamma cites data by Google España that 85% of Spanish patients access the web as the first port-of-call for healthcare-related information and after receiving medical advice; it also claims that 20% of all Internet searches are for health-related information. The relaunched website (www.ascamma.org) has links to the national medical oncology society (SEOM) and the national association for immediate reconstructive surgery (AERMI), among other organisations; it is sponsored by Roche. Ascamma is a vocal campaigner for breast cancer screening and early diagnosis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel